EAS Journal of Biotechnology and Genetics
Abbreviated Key Title: EAS J Biotechnol Genet
ISSN: 2663-189X (Print) & ISSN: 2663-7286 (Online)
Published By East African Scholars Publisher, Kenya

OPEN ACCESS

Volume-8 | Issue-2 | Apr-Jun-2026 | DOI: https://doi.org/10.36349/easjbg.2026.v08i02.001

Review Article

Nanobiotechnology in Cancer Diagnosis and Targeted Therapy: Recent Advances

Omar Hussein Harran[1]*, Amerah Abdul Hadi[2]

[1]Department of Agricultural Biotechnology, College of Biotechnology, University of Al-Qadisiyah, Al Diwaniyah, Iraq
[2]Department oral diagnosis, College of Dentistry, University of Kerbela, 56001, Karbala, Iraq

Article History
Received: 06.02.2026
Accepted: 31.03.2026
Published: 02.04.2026

Journal homepage:
https://www.easpublisher.com

Quick Response Code

Abstract: Nanobiotechnology has made a significant impact in the field of cancer treatment and diagnosis, as it merged the finest aspects of materials science, molecular biology, and clinical medicine to give the process a new level of precision and quality. Presently nanoparticles are engineered to be cross agents—very different from the past when they would be simply designed to be in blood circulation for long time, detect the tumor area, notify the cell's condition by their own and drug delivery in the predetermined way. The processing of modern innovations has been grouped into five related areas: rational materials designing and surface functionalization; the application of nanoparticles for diagnostics and liquid biopsy platforms; precision delivery systems with stimuli-responsive release; the establishment of integrated theragnostic constructs that embrace imaging and therapy; and the assessment of the translational challenges of safety, manufacturability, and regulation. We proposed design principles that balance the durability of circulation with the penetration of the tissue, talked about the analytical advantages supplied by nanoscale contrast agents and biosensors for detection that is earlier and more specific, and reviewed the approaches for delivery that merge active targeting and responsive chemistries to increase on-target efficacy and at the same time reduce systemic toxicity. The use of multimodal imaging reporters and therapeutic modalities in combination as theragnostic platforms has provided few advantages among which real-time monitoring and adaptive therapies are the one. Yet, the issues of the practical clinical translation that were previously mentioned—robust characterization, mechanism-focused toxicology, immunogenicity profiling, scalable manufacturing, and regulatory alignment—must still be dealt with; hence we still need to maintain that multidisciplinary development pathways and companion diagnostics are critical for having an influence in the clinic. It is hard to imagine precision oncology without nanobiotechnology that not only provides a toolkit but also a strategic platform through combining mechanistic understanding with translational realism. We conclude by offering practical recommendations for speeding up the process of safe and equitable adoption in clinical practice.

Keywords: Cancer, Nanobiotechnology, Targeted Therapy.

INTRODUCTION

Cancer is still a major problem worldwide and improving survival and quality of life through earlier detection and better therapies is still a priority. Nanobiotechnology is a branch of science that deals with the application of nanotechnology to biological problems. It can create materials and devices that work with tumors at the level of molecules and cells. Conventional single-function agents are different from engineered nanoparticles, which can be given cooperatively, i.e., prolonged circulation, selective binding, enhanced imaging contrast, and programmable payload release, thus a single construct being able to interrogate disease, deliver therapy, and report response. The functionalities mentioned above create new clinical paradigms: the possibility of early disease detection by minimally invasive liquid biopsies, techniques guided by images that prevent surrounding tissue from being affected, and the use of adaptive treatment strategies

***Corresponding Author:** Omar Hussein Harran
Department of Agricultural Biotechnology, College of Biotechnology, University of Al-Qadisiyah, Al Diwaniyah, Iraq

based on real-time biomarker feedback. Nevertheless, the potential of nanotechnology relies greatly on meticulous, systemic design. Selection of the core substance, control over the dimensions and the form, surface chemistry, and ligand architecture all combine to determine the pharmacokinetics, the extent of penetration through the tumor, the interactions with the immune system, and the safe use of the product. Manufacturing, quality control during production, and stability during storage are some of the practical issues that must be taken into account when making design decisions from the very beginning if clinical usability is to be guaranteed. From a diagnostics point of view, the use of nanomaterials in contrast agents and sensors not only increases the sensitivity and specificity in imaging and molecular assays but also allows for the detection of circulating tumor cells, extracellular vesicles, and cell-free nucleic acids at concentrations which are clinically relevant. Therapeutics, development of lipid and polymeric carriers has facilitated the systemic administration of nucleic acids and multi-component payloads, while the use of stimuli-responsive chemistries allows the timed release of the drug in a specific area of the tumor microenvironment. Theragnostic scaffolds that combine imaging and treatment have the potential to reduce decision-making times and tailor patient treatments, but at the same time they will complicate the whole process of production and regulation. The review presented here is a comprehensive literature examination which overall points out the recent developments and increased collaboration that happened in the areas of rational design of nanoparticles, nano-diagnostics, precise drug delivery systems, integrated theragnostic, and translational science, and consequently presents a workable model whereby researchers and practitioners in the medical field can effectively align the impacts of technological innovations with clinical pathways. The translation of clinical findings into practice will involve the collaboration of professionals from various disciplines, the development of reliable companion diagnostics, and the establishment of common evaluation criteria that will show patient-centered benefit and the potential for large-scale usage.

The Architect's Toolkit: Rational Design and Functionalization of Nanoparticles for Oncology

Rational nanoparticles for cancer treatment are made through the process of meticulous engineering rather than building catalogues. It involves choosing the right materials for the core, controlling the particle size and shape, and designing the surface chemistry to ensure that the particle has a predictable behavior in the blood, goes through the tumor microenvironment, and releases the drug at the right time and place. The basic design principles such as controlling size, aspect ratio, mechanical stiffness, and surface charge, still have the most significant impact on circulation half-life, tumor extravasation and cellular uptake, and for these parameters to be effective, they should be adjusted together, not separately. (Mitchell *et al*., 2021). The contemporary "smart" systems increase the range of applications by integrating different materials (lipid, polymer, inorganic) with responsive elements to provide functionality as per need. (e.g., charge conversion, ligand exposure, size shrinkage) Reconciling the conflicting claims made by circulation versus penetration into the tumor (Sun *et al.,* 2023).

Material-specific strategies are also required by rationalization. On the one hand, liposomes and polymeric carriers provide good compatibility with the body and easy drug encapsulation, but they are highly dependent on surface shielding. (e.g., PEGylation) and restrict ligand exposure density to disallow premature cleaning and thus to effect selective binding. (Mitchell *et al*., 2021; Sun *et al*., 2023). Gold nanoparticles and quantum dots, to name a few, are inorganic scaffolds that possess extraordinary optical or magnetic properties which can be utilized in imaging and photothermal therapy applications. However, in order to control the formation of the protein corona, to minimize the unspecific localization, and to ensure the stable bioconjugation of antibodies, peptides or oligonucleotide aptamers, their surface chemistry needs to be engineered properly. (Villalobos Gutiérrez *et al*., 2023). Systems-level thinking is exemplified by rational design such as nanoparticles that are specifically designed to either trigger immunogenic cell death or to reveal organelle-targeting motifs after undergoing enzymatic cleavage—methods that necessitated the incorporation of biological signals into chemical synthesis from the very beginning. (Zhang *et al*., 2024).

Surface functionalization is the cornerstone: stealth coatings (PEG, zwitterions), covalent and non-covalent ligand attachment, linker design (cleavable vs. permanent), and multivalent presentation are the factors that alter the affinity, avidity, and downstream trafficking of the carrier. (Mitchell *et al*., 2021; Yan *et al*., 2024). In the choice of targeting ligand the application dictates the need, in the case of full antibodies it is for high affinity and effector function, in the case of peptide small-footprint targeting and tumor-penetration, and in the case of aptamers it is for chemical synthesis and low immunogenicity being the priorities and now the literature documents systematic comparisons and hybrid strategies that combine more than one ligand type for hierarchical targeting. (Wei *et al*., 2022; Yan *et al*., 2024). Pragmatic engineering, however, necessitates early consideration of manufacturability, stable conjugation chemistries that can be replicated, and the determination of how functionalization affects pharmacokinetics and toxicity profiles. Such restrictions in translation should be incorporated into the "architect's" blueprint from the very first day (Mitchell *et al*., 2021; Sun *et al*., 2023).

Nano-Sleuths: Advanced Diagnostic Modalities and Early Detection Strategies

Nanobiotechnology has completely changed our perspective on cancer, and it did not only by amplifying the signal but also by converting the probes into active investigators that stealthily look for, uncover, and measure tumor-associated signals even at the lowest levels that were impossible to reach before. Nanoparticle contrast agents play a significant role in imaging by the extension of sensitivity and the complementarity of modalities: the enhancement of photoacoustic contrast by designer plasmonic and dye-loaded nanoparticles, and the facilitation of thorough and clear vascular and lymphatic mapping at great depths, thus, are the capabilities of the latter. (Sridharan & Lim, 2023), The use of high-Z and lanthanide-doped nanomaterials has been able to give a significant amount of time and control over the X-ray attenuation for CT and multimodal CT/MR which not only enhances the visibility of the lesions but also allows the interventions to be guided by the images taken. (Jiang *et al*., 2023). These nano-contrast mechanisms are being created not merely for the purpose of enhancing the visibility of the anatomy, but rather for the communication of the molecular states. (e.g., protease activity, pH) (Sridharan & Lim, 2023; Jiang *et al*., 2023).

Nanoscale sensors have significantly reduced the detection limits for liquid-biopsy analytes at the same time as imaging. The nano-electrochemical, optical and plasmonic assays made possible by nanomaterials exploit signal boosting, high surface area and specially designed recognition chemistries to detect circulating tumor cells (CTCs), exosomes, and cell-free DNA at the level of femtomolar or even single-particle counting. (Lee *et al*., 2022). The platforms that focus on exosomes and combine metal/graphene/MOF hybrids with aptamer or antibody recognition have demonstrated their ability to deliver sensitive, multiplexed cargo readouts (proteins, miRNA) from tiny plasma volumes - which is a huge benefit for early detection and continuous monitoring. (Lee *et al*., 2022; Yu *et al*., 2022). Exosomes, notably, convey tumor-specific molecular signatures and maintain a greater stability than free nucleic acids in the bloodstream; hence, they are deemed as attractive targets for both discovery and clinical assays. (Yu *et al*., 2022).

Nanotechnology has had a complementary effect on ctDNA detection. Recently, electrochemical biosensors had increasingly used nanoparticle labels, enzyme-assisted circuits for amplification, and nanostructured electrodes to get to the analytical sensitivity levels suitable for monitoring minimal residual disease (MRD) and early detection, while at the same time, reducing analysis time and the size of the instrument — an evident advance in the direction of decentralized testing. (Kumar *et al*., 2024). Because of the novel detection method, it will be possible to monitor even very small and subtle changes of clinically actionable alterations through non-invasive techniques and without the expensive and complex process of whole-genome sequencing, though uniformity and cross-platform validation still will be required. (Kumar *et al*., 2024).

Because of the novel detection method, it will be possible to monitor even very small and subtle changes of clinically actionable alterations through non-invasive techniques and without the expensive and complex process of whole-genome sequencing, though uniformity and cross-platform validation still will be required. Today's chips combine affinity-based nanocapture (by magnetic or functionalized nanostructures), on-chip amplification, and multiplexed detection for sample-to-answer performance in identifying Circulating Tumor Cells (CTCs), exosomes, and circulating tumor DNA (ctDNA) from just a single small blood draw. (Özyurt *et al*., 2023). Such techniques minimize differences in pre-analytical conditions and support the use of longitudinal sampling schemes that are necessary for the timely detection of diseases and treatment monitoring. (Özyurt *et al*., 2023).

Unquestionably, there are still several practical difficulties to be recognized along with the spectacular analytical performance. Assay reproducibility and specificity are definitely challenged by protein corona formation, batch variability in nanoparticle synthesis, and matrix effects in complex biofluids; however, rigorous, head-to-head clinical validation against established modalities is still lacking and hardly seen. (Lee *et al*., 2022; Kumar *et al*., 2024). In the same manner, the imaging contrast substances have to manage the prolonged signal together with rapid and safe elimination and low off-target retention, all of which are very important factors closely related to surface texture and particle size. (Jiang *et al*., 2023; Sridharan & Lim, 2023). Successful clinical adoption ultimately demands standardized protocols, external quality controls, and regulatory-grade evidence of clinical utility (Yu *et al*., 2022; Özyurt *et al*., 2023).

Eventually, diagnostics have been transformed by nanobiotechnology from "can we see?" to "what is it?" and "how is it behaving?" The particle-enhanced imaging, ultrasensitive biosensors, and integrated lab-on-chip devices have together contributed a complementary toolkit to earlier, more specific cancer detection. The next phase is rigorous clinical validation and standardization of such nano-diagnostics to routinely inform bedside decisions.

Precision Payloads: Targeted Drug Delivery and Controlled Release Mechanisms

The main point of precision oncology is to transport the therapeutic cargo straight into the tumor and then let it go so that it can work on delivering the whole load to the intended location—where the modern nanovehicles are designed and customized for this

purpose. The recent surveys have come down to this great "triad" discussion. (Small molecules, proteins, siRNA/mRNA, and immunomodulators), (2) the ways we use to deliver the payload precisely (passive vs. active targeting, multi-stage designs), and (3) the release and control mechanisms (chemistry, microenvironmental or external stimuli, and intracellular escape strategies) (Cheng *et al*., 2023).

The variety of payloads has quickly expanded. Traditional pharmacological agents still play a significant role, but other innovative and advanced formulations like nucleic-acid drugs (siRNA, mRNA) and immune payloads (cytokines, checkpoint modulators, cancer vaccines) have come to be recognized as feasible because of breakthroughs in formulation and endosomal-escape chemistries—lipid nanoparticles (LNPs) in particular have not only demonstrated the clinical feasibility of systemic RNA delivery but also offered a roadmap for oncology applications. (Hou *et al*., 2021; Moazzam *et al*., 2024). LNPs are a prime example of how formulation (ionizable lipids, helper lipids, and PEG-lipids), particle size, and surface composition in combination to decide the circulation patterns, organ distribution, and the crucial trade-off between delivery efficacy and tolerability. (Hou *et al*., 2021).

Strategies for targeting are determined by the specific use cases. The passive accumulation technique through the enhanced permeability and retention (EPR) effect can bring about the concentration of particles in several preclinical models, but human tumors are diverse and EPR alone is not a reliable delivery method so modern ways of treating tumors now prefer to combine the use of targeting agents (antibodies, peptides, aptamers) with the use of physical means (mild hyperthermia, vascular modulation) or to use multi-stage carriers that vary size/charge in vivo to first accumulate and then penetrate. (Cheng *et al*., 2023; Sharifi *et al*., 2022). In the case of nucleic-acid therapeutics, the preference of the field has been towards lipid and hybrid lipid platforms due to their capability to encapsulate polyanionic cargos and their compatibility with endosomal release; nonetheless, polymeric and inorganic systems continue to be important for the tasks of co-delivery or controlled release. (Moazzam *et al.,* 2024; Cheng *et al*., 2023).

Controlled release is no longer considered an afterthought but rather a sophisticated design variable. The stimuli-responsive linkers and matrices can be triggered by various factors including the acidic pH, high tumor proteases, high intracellular glutathione (low redox potential), temperature, light, or ultrasound, making it possible for the payloads to be hidden throughout the circulation period and then to release the drugs only in the tumor or target cells. (Zhang *et al*., 2022; Handa *et al*., 2022). Among the examples are acid-labile hydrazone linkers that release doxorubicin in endosomes, enzyme-cleavable peptide linkers that hide targeting moieties, redox-sensitive disulfide bonds for liberation of intracellular payloads, and charge-reversal polymers that make cellular uptake easier before they turn into a release-competent state. (Zhang *et al*., 2022; Handa *et al*., 2022).

Among the examples are acid-labile hydrazone linkers that release doxorubicin in endosomes, enzyme-cleavable peptide linkers that hide targeting moieties, redox-sensitive disulfide bonds for liberation of intracellular payloads, and charge-reversal polymers that make cellular uptake easier before they turn into a release-competent state. (Hou *et al*., 2021; Moazzam *et al*., 2024). Second, co-delivery and synergy — the co-treatment of a cytotoxic drug with an RNA molecule that shuts down a resistance mechanism or the combination of a checkpoint inhibitor with a tumor vaccine can be achieved through core-shell or co-encapsulation strategies which will require meticulous regulation of the release kinetics to ensure that one agent does not neutralize the effect of the other. (Cheng *et al*., 2023; Zhang *et al*., 2022).

Ultimately, translational realities play an essential role in every single design decision made. The robustness of manufacturing, the ability to scale up the production of reproducible encapsulation and ligand conjugation, stability during storage, and predictable pharmacokinetics are factors that are equally important as aesthetic triggers; moreover, interpatient heterogeneity (tumor vascularity, protease levels, immune status) creates a need for companion diagnostics and adaptive dosing strategies instead of a universal particle being used for all. (Cheng *et al*., 2023; Sharifi *et al*., 2022). To sum it up, today's "precision payloads" are the outcome of chemical creativity, biological knowledge, and practical engineering — the development of carriers that transport the correct agent, to the correct cell, and at the correct time.

Theranostics: Integrating Diagnosis and Therapy in a Single Nanoplatform

Theragnostic nanoplatforms revolutionize the previous separation between "diagnosis" and "therapy" by fusing the imaging reporters, therapeutic agents, and stimulus-driven reactions into one, customizable particle. The cutting-edge nano-theragnostics are designed to (1) detect tumor site and molecular status with great sensitivity (MRI, PET, CT, photoacoustic and NIR imaging), (2) administer a certain type of therapy (chemotherapy, photothermal/photodynamic therapy, immunomodulators, radiotherapy enhancers or gene therapy) and (3) give feedback on the patient's response to treatment instantly, allowing the doctors to change the therapy right away. (Kashyap *et al*., 2023). The integrated capacity facilitates the performance of image-guided dose escalation, intraoperative tumor delineation, and the serial assessment of pharmacodynamics—

beyond any doubt, these are the main components of truly personalized oncology. (Gupta *et al*., 2024).

The numerous design patterns are successful. In the first place, multimodal inorganic cores—iron-oxide or rare-earth-doped nanoclusters combined with gold or bismuth, for instance—supply the integration of MRI/CT/PA contrast with heat mediation for magnetic and photothermal therapies; the dual-purpose cores that are of both varieties allow for the localization of both long range (CT/MRI) and real-time functional imaging (photoacoustic) during the therapy (Zhang *et al*., 2022; Brito *et al*., 2021). Furthermore, the second type of stimuli-responsive theragnostic relies on either tumor microenvironment signals (which include low pH, high protease activity, lack of oxygen, and redox gradients) or on external stimuli (such as light, ultrasound, and magnetic fields) to reveal the application of therapeutics and reporters just at the disease site, thus increasing on-target efficacy and simultaneously decreasing systemic toxicity. (Kashyap *et al*., 2023; Gupta *et al*., 2024). Thirdly, the various surfaces like biomimetic and stealth (cell-membrane coatings, albumin-based coronas, zwitterionic shells) prolong the circulation, diminish their immunogenicity, and occasionally grant homotypic targeting, which is very advantageous for image-guided delivery and for keeping the reporter function intact just long enough to assist the therapy. (Zhang *et al*., 2022; Brito *et al*., 2021).

Among the optical theragnostic, photoacoustic and NIR-II have been particularly recognized and even more so in their applications in the operating room and for phototherapy: this is due to the innovative design of the nanoprobe which emits bright NIR-II fluorescence/photoacoustic signals and at the same time has good photothermal conversion efficiency allowing the surgeon to delineate the tumor extent below the surface and subsequently remove the remaining cancerous tissue using the same imaging technique. (Sridharan & Lim, 2023; Zhang *et al*., 2022). On the other hand, MR-traceable platforms are still essential for deep-tissue planning and long-term monitoring, as the iron- or gadolinium-based constructs not only provide high anatomical fidelity but also can be designed to transport radiosensitizers or controlled-release drugs. (Anani *et al*., 2021; Brito *et al*., 2021).

The journey from preclinical trials to human therapy for theragnostic is still very difficult notwithstanding the outstanding results in the preclinical trials. The huge complexity of the production (multicomponent particles with precise stoichiometry), regulatory hurdles for agents that are at the same time a device, drug, and diagnostic, the long-term safety issue (bioaccumulation of inorganic cores), and the requirement of companion-diagnostic workflows to choose responsive patients are all active bottlenecks. (Kashyap *et al*., 2023; Gupta *et al*., 2024). It is still probable that the first significant therapeutic effect of application will be through limited use, where imaging significantly affects the decision-making process such as in image-guided removal, focal destruction, or radiosensitivity, rather than through the extensive substitution of conventional chemo with the whole systemic treatment. (Anani *et al*., 2021; Brito *et al*., 2021).

Theragnostic, in brief, provides the most convenient way to precision oncology: the use of engineered nanoparticles that detect the exact location of the tumor, deliver the drug, and reveal if the drug was effective — all ideally during the same clinical appointment. The field's immediate priorities comprise (a) reconciling production and quality measures for sophisticated nanoplatforms, (b) creating strict, indication-specific clinical endpoints that demonstrate superiority over present standards and hence, prove added value, and (c) developing biodegradable or easily eliminated constructs to reduce long-term safety issues thus allowing theragnostic to pass through dramatic preclinical demonstrations and become part of continuous patient care. (Kashyap *et al*., 2023; Gupta *et al*., 2024; Anani *et al*., 2021).

Bridging the Bench and the Bedside: Clinical Translation, Toxicity, and Regulatory Hurdles

Nanobiotechnology application in cancer treatment, which may be effective and safe for humans, and become legal, is a long process that goes beyond showing good results in mice. Rather, it calls for a multidisciplinary approach that combines pharmacology, toxicology, manufacturing (CMC), clinical strategy, and regulatory science from the outset. (Đorđević *et al*., 2022). The practical challenges can be divided into multiple dependent categories: reproducible production and characterization, predictable pharmacokinetics/bioavailability, safety (both short-term and long-term), immunogenicity, proper preclinical models and biomarkers, and a regulatory route that is capable of managing multi-component, hybrid products. (Mitchell *et al*., 2021; Clogston *et al*., 2024).

The production and quality assurance processes act as decisive gatekeepers. Nanoparticle products are influenced heavily by slight variations in process parameters (e.g., mixing energy, solvent ratios, temperature, ligand-coupling efficiency), and these variations can cause changes in the size, charge, drug loading, and eventually the safety/efficacy profile. Regulatory reviewers are putting more attention on CMC filings that provide batch control, specified critical quality attributes (CQAs), and strong analytical methods for physicochemical characterization (particle size distribution, surface chemistry, free vs. bound drug, endotoxin, aggregates) — any one of these weaknesses will delay or prohibit clinical approvals. (Clogston *et al*., 2024; Đorđević *et al*., 2022).

The behavior of pharmacokinetics and biodistribution for a particle differs fundamentally from that of a small molecule. Moreover, nanocarriers have the unique pharmacological property of being the carrier itself that affects the efficacy and toxicity of the payload. Some of the problems are liver and spleen sequestration, contrasting renal and hepatobiliary clearances, as well as prolonged storage of inorganic cores. Thus, it follows that experiments will have to consider both drug release and nanoparticle residues over suitable periods of time, and they will also need to carry out sensitive tissue analyses to find any low-level accumulation that might eventually become clinically significant. (Mitchell *et al*., 2021; Zhang *et al*., 2022).

Standard acute dosing should not the only consideration as far as toxicity assessment is concerned. Nanoparticles may inflict particular toxicities (complement activation-related pseudo allergy, rapid blood clearance, particle-induced inflammation, organ-specific accumulation and, for a few inorganic materials, slow biodegradation with chronic exposure risk). Toxicity mechanisms like oxidative stress, membrane disruption, and the formation of the protein corona should be taken into consideration for making small changes in the product design that will reduce the risk. (Zhang *et al*., 2022). It is no longer an option of conducting parallel safety pharmacology, immunotoxicity, and biodistribution studies under GLP conditions for late-stage programs. (Đorđević *et al*., 2022; Zhang *et al*., 2022).

Immunogenicity is something that has both pros and cons. Certain systems like lipid nanoparticles purposely provoke the innate immune system to enhance the efficacy of vaccines, however, that very effect may lead to side effects or make it impossible to give further doses in case of therapy. The main clinical concerns are the changes in the tolerability and pharmacokinetics caused by complement activation, anti-PEG antibodies, and innate sensor activation. It is of utmost importance to conduct an early and systematic immunoprofiling (cytokines, complement, anti-excipient antibodies) under the appropriate dosing regimens, while at the same time the design strategies (altered lipid chemistries, reduced PEG content, alternative stealth coatings) should be based on such data. (Lee *et al.*, 2023; Mitchell *et al*., 2021).

There is an urgent need to bring preclinical models and biomarkers up to date. The standard mouse tumor models and the sole endpoint readouts frequently underestimate the difficulties to deliver the drugs to humans (tumor heterogeneity, stroma, interstitial pressure). The direction of the field is towards multiparametric preclinical pipelines that involve advanced 3D models, patient-derived xenografts, organ-on-chip (microphysiological systems) and single-vessel imaging which are more accurate in estimating intratumorally transport and retention. In a similar way, companion diagnostics and early pharmacodynamic biomarkers (like imaging tracers and circulating biomarkers) enhance the decision-making process (go/no-go) and the selection of patients in trials with humans for the first time. (Mitchell *et al*., 2021; Đorđević *et al*., 2022).

While the regulatory expectations are changing, they are nevertheless still detached from one another. The Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other agencies have provided instructions and debate documents; however, the situation regarding nanomedical products is such that they often cross over various regulatory categories (i.e., a drug, a device, a biologic or a combination product), thus making it difficult to prepare the dossier. The clinical translation that turns out to be successful is generally the result of the programs that involve the regulators at an early stage (scientific advice/innovation offices), present clearly defined CQAs and nonclinical packages, and suggest unambiguous clinical endpoints along with monitoring plans for particle fate and immunogenicity. (Clogston *et al*., 2024; Gawne *et al*., 2023). The elocity of real-life recently approved drugs (such as siRNA LNPs and vaccine LNPs) has demonstrated that the regulators are ready to consider new platforms if they are backed by thorough, mechanism-informed safety, and quality data. (Clogston *et al*., 2024; Lee *et al*., 2023).

Practical strategies whose execution would lead to faster translation and fewer ro failures include the following: (1) design for manufacturability (conjugation chemistries and excipients should be chosen that can be scaled up), (2) define CQAs and establish orthogonal analytics early on, (3) perform mechanism-driven toxicology and immunoprofiling studies, (4) adopt more predictive preclinical models and quantitative imaging methods to measure delivery, and (5) engage regulators early in the process to agree on comparability and clinical monitoring expectations. (Đorđević *et al*., 2022; Mitchell *et al*., 2021; Clogston *et al*., 2024). Multi-disciplinary teams (such as chemists, toxicologists, process engineers, etc.) that work together — not one after the other — to facilitate the development process of concurrent programs are a common trait of successful ones. In conclusion, the route from basic research to medical application for cancer nanomedicine is arduous but possible: the result depends more on the strict, composite production—that is, reproducible manufacturing, thorough safety and immunology studies, contemporary preclinical validation, and open regulatory engagement—than one "miraculous" nanoparticle. There are many points that must reach consensus before the full potential of nanobiotechnology for advanced and safer faults in cancer diagnosis and treatment is unleashed (Gawne *et al*., 2023; Đorđević *et al.*, 2022).

CONCLUSION

Nanobiotechnology is now at a very important juncture: it has advanced from mere single proofs of concept to the actual creation of platforms that can change cancer detection, monitoring, and treatment. The maximum benefit of this technology, however, will not be the result of a specific "magic" particle, but rather the interdisciplinary advancements in designing, diagnostic works, delivery, and translational activities becoming the major force. The use of nanoparticles will have to be mechanistically informed; nano-based diagnostics that could meddle with clinical decisions should be certified; precision delivery systems that would allow safe and repeatable dosing should be put in place; and realistic manufacturing and regulatory approaches that would guarantee reproducibility and patients' safety should be established. It is essential to thoroughly consider clinical integration before applying it introducing companion diagnostics, using adaptive trial designs, and establishing clear patient-centered endpoints that show significant benefit. During the development process, equity and access issues must be considered to prevent the disparity between cancer treatments offered to various patients from getting worse. Immunogenicity, long-term biodistribution, and process variability, which are the known risks, can be evaluated if they are detected early and prevented by rigorous preclinical testing and incubate design. The most effective path going forward can be described as a fusion of immense scientific imagination and translational efficiency, which is marked by the presence of regulatory and manufacturing proficiency in interdisciplinary teams right from the inception of the project, the use of common metrics for comparison of different platforms, and the conducting of clinical trials in a manner that would be evident for the indications to which nanoparticle techniques would provide the most ganging up of advantages. Under such circumstances, nanobiotechnology will act as a clinically beneficial, promising platform for precision oncology—permitting the earlier detection of cancer, the deployment of the most effective targeted therapies, and the application of treatment approaches that are situation-aware and hence, increase the results while decreasing the side effects.

REFERENCES

- Anani, T., Rahmati, S., Sultana, N., & David, A. E. (2021). *MRI-traceable theranostic nanoparticles for targeted cancer treatment.* Theranostics, 11(2), 579–601. https://doi.org/10.7150/thno.48811
- Brito, B., Price, T. W., Gallo, J., Bañobre-López, M., & Stasiuk, G. J. (2021). *Smart magnetic resonance imaging-based theranostics for cancer.* Theranostics, 11(18), 8706–8737. https://doi.org/10.7150/thno.57004
- Cheng, X., Xie, Q., & Sun, Y. (2023). Advances in nanomaterial-based targeted drug delivery systems. *Frontiers in Bioengineering and Biotechnology, 11*, 1177151. https://doi.org/10.3389/fbioe.2023.1177151
- Clogston, J. D., Foss, C. A., & [others]. (2024). Current state of nanomedicine drug products: An industry perspective. *Journal of Pharmaceutical Sciences.* https://doi.org/10.1016/j.xphs.2024.09.005
- Đorđević, S., Gonzalez, M. M., Conejos-Sánchez, I., Carreira, B., Pozzi, S., Acúrcio, R. C., Satchi-Fainaro, R., Florindo, H. F., & Vicent, M. J. (2022). Current hurdles to the translation of nanomedicines from bench to the clinic. *Drug Delivery and Translational Research, 12*(3), 500–525. https://doi.org/10.1007/s13346-021-01024-2
- Gawne, P. J., Ferreira, M., Papaluca, M., Grimm, J., & Decuzzi, P. (2023). New opportunities and old challenges in the clinical translation of nanotheranostics. *Nature Reviews Materials, 8*(12), 783–798. https://doi.org/10.1038/s41578-023-00581-x.
- Gupta, D., Roy, P., Sharma, R., Kasana, R., Rathore, P., & Gupta, T. K. (2024). *Recent nanotheranostic approaches in cancer research.* Clinical and Experimental Medicine, 24, Article 8. https://doi.org/10.1007/s10238-023-01262-3
- Handa, M., Singh, A., Flora, S. J. S., & Shukla, R. (2022). Stimuli-responsive polymeric nanosystems for therapeutic applications. *Current Pharmaceutical Design, 28*(11), 910–921. https://doi.org/10.2174/1381612827666211208150210
- Hou, X., Zaks, T., Langer, R., & Dong, Y. (2021). Lipid nanoparticles for mRNA delivery. *Nature Reviews Materials, 6*(12), 1078–1094. https://doi.org/10.1038/s41578-021-00358-0
- Jiang, Z., Zhang, M., Li, P., Wang, Y., & Fu, Q. (2023). *Nanomaterial-based CT contrast agents and their applications in image-guided therapy.* Theranostics, 13(2), 483–509. https://doi.org/10.7150/thno.79625
- Kashyap, B. K., Singh, V. V., Solanki, M. K., Kumar, A., Ruokolainen, J., & Kesari, K. K. (2023). *Smart nanomaterials in cancer theranostics: Challenges and opportunities.* ACS Omega, 8(16), 14290–14320. https://doi.org/10.1021/acsomega.2c07840
- Kumar, S., Poria, R., Kala, D., Nagraik, R., Dhir, Y., Dhir, S., Singh, B., Kaushik, N. K., Noorani, M. S., Kumar, D., *et al.* (2024). *Recent advances in ctDNA detection using electrochemical biosensor for cancer.* Discover Oncology, 15, 517. https://doi.org/10.1007/s12672-024-01365-7
- Lee, M., Kim, J., Jang, M., Park, C., Lee, J.-H., & Lee, T. (2022). *Introduction of nanomaterials to biosensors for exosome detection: Case study for cancer analysis.* Biosensors, 12(8), 648. https://doi.org/10.3390/bios12080648
- Lee, Y., Jeong, M., Park, J., Jung, H., & Lee, H. (2023). Immunogenicity of lipid nanoparticles and

its impact on the efficacy of mRNA vaccines and therapeutics. *Experimental & Molecular Medicine, 55*, 2085–2096. https://doi.org/10.1038/s12276-023-01086-x

- Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., & Langer, R. (2021). *Engineering precision nanoparticles for drug delivery.* Nature Reviews Drug Discovery, 20, 101–124. https://doi.org/10.1038/s41573-020-0090-8
- Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., & Langer, R. (2021). Engineering precision nanoparticles for drug delivery. *Nature Reviews Drug Discovery, 20*, 101–124. https://doi.org/10.1038/s41573-020-0090-8
- Moazzam, M., Zhang, M., Hussain, A., Yu, X., Huang, J., & Huang, Y. (2024). The landscape of nanoparticle-based siRNA delivery and therapeutic development. *Molecular Therapy, 32*(2), 284–312. https://doi.org/10.1016/j.ymthe.2024.01.005
- Özyurt, C., Uludağ, İ., İnce, B., & Sezgintürk, M. K. (2023). *Lab-on-a-chip systems for cancer biomarker diagnosis.* Journal of Pharmaceutical and Biomedical Analysis, 226, 115266. https://doi.org/10.1016/j.jpba.2023.115266
- Sharifi, M., Cho, W. C., Ansariesfahani, A., Tarharoudi, R., Malekisarvar, H., Sari, S., Bloukh, S. H., Edis, Z., Amin, M., Gleghorn, J. P., Ten Hagen, T. L. M., & Falahati, M. (2022). An updated review on EPR-based solid tumor targeting nanocarriers for cancer treatment. *Cancers, 14*(12), Article 2868. https://doi.org/10.3390/cancers14122868
- Sridharan, B., & Lim, H. G. (2023). *Advances in photoacoustic imaging aided by nano contrast agents: Special focus on role of lymphatic system imaging for cancer theranostics.* Journal of Nanobiotechnology, 21, Article 437. https://doi.org/10.1186/s12951-023-02192-8
- Sridharan, B., & Lim, H. G. (2023). *Advances in photoacoustic imaging aided by nano contrast agents: Special focus on role of lymphatic system imaging for cancer theranostics.* Journal of Nanobiotechnology, 21, Article 437. https://doi.org/10.1186/s12951-023-02192-8
- Sun, L., Liu, H., Ye, Y., Lei, Y., Islam, R., Tan, S., Tong, R., Miao, Y.-B., & Cai, L. (2023). *Smart nanoparticles for cancer therapy.* Signal Transduction and Targeted Therapy, 8, Article 418. https://doi.org/10.1038/s41392-023-01642-x
- Villalobos Gutiérrez, P. T., Muñoz Carrillo, J. L., Sandoval Salazar, C., Viveros Paredes, J. M., & Gutiérrez Coronado, O. (2023). *Functionalized metal nanoparticles in cancer therapy.* Pharmaceutics, 15(7), 1932. https://doi.org/10.3390/pharmaceutics15071932
- Wei, Z., Zhou, Y., Wang, R., Wang, J., & Chen, Z. (2022). *Aptamers as smart ligands for targeted drug delivery in cancer therapy.* Pharmaceutics, 14(12), 2561. https://doi.org/10.3390/pharmaceutics14122561
- Yan, S., Na, J., Liu, X., & Wu, P. (2024). *Different targeting ligands-mediated drug delivery systems for tumor therapy.* Pharmaceutics, 16(2), 248. https://doi.org/10.3390/pharmaceutics16020248
- Yu, D., Li, Y., Wang, M., Gu, J., Xu, W., Cai, H., Fang, X., & Zhang, X. (2022). *Exosomes as a new frontier of cancer liquid biopsy.* Molecular Cancer, 21, 56. https://doi.org/10.1186/s12943-022-01509-9
- Zhang, J., et al. (2022). Stimuli-responsive nanoparticles for controlled drug release. *Advanced Science.* https://doi.org/10.1002/advs.202103444
- Zhang, L., Liu, Y., Huang, H., Xie, H., Zhang, B., Xia, W., & Guo, B. (2022). *Multifunctional nanotheranostics for near infrared optical imaging-guided treatment of brain tumors.* Advanced Drug Delivery Reviews, 190, 114536. https://doi.org/10.1016/j.addr.2022.114536
- Zhang, N., Xiong, G., & Liu, Z. (2022). Toxicity of metal-based nanoparticles: Challenges in the nano era. *Frontiers in Bioengineering and Biotechnology, 10.* https://doi.org/10.3389/fbioe.2022.1001572
- Zhang, Z., et al. (2024). *Rationally designed immunogenic-cell-death (ICD) inducing nanoparticles for enhanced anticancer immunity.* Science Advances. https://doi.org/10.1126/sciadv.adk0716

Cite This Article: Omar Hussein Harran & Amerah Abdul Hadi (2026). Nanobiotechnology in Cancer Diagnosis and Targeted Therapy: Recent Advances. *EAS J Biotechnol Genet, 8*(2), 7-14.